Biotech | November 23, 2021
AstraZeneca opens Discovery Centre in Cambridge
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
Obseva announced previously that the company has entered into a partnership with Syneos Health to support commercialization of linzagolix in the US and EU
Hospitals and outpatient clinics can also digitally navigate patients from the time an order is placed, to when it is scheduled and completed through follow-up
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
The nutraceutical sector is on the cusp of exponential growth and Covid-19 has accelerated the pace of its applications. Dr R.B Smarta, CMD, Interlink, shares his perspective on the growth opportunities and challenges for the sector
First-of-its-kind Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics
The system is a compact new addition to the Roche Molecular portfolio, providing efficiency, simplicity and timely results to laboratories of all sizes.
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
Subscribe To Our Newsletter & Stay Updated
